Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C20H22O8 |
| Molecular Weight | 390.3839 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 5 / 5 |
| E/Z Centers | 1 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OC[C@H]1O[C@@H](OC2=CC(O)=CC(\C=C\C3=CC=C(O)C=C3)=C2)[C@H](O)[C@@H](O)[C@@H]1O
InChI
InChIKey=HSTZMXCBWJGKHG-CUYWLFDKSA-N
InChI=1S/C20H22O8/c21-10-16-17(24)18(25)19(26)20(28-16)27-15-8-12(7-14(23)9-15)2-1-11-3-5-13(22)6-4-11/h1-9,16-26H,10H2/b2-1+/t16-,17-,18+,19-,20-/m1/s1
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/23862567Curator's Comment: Description was created based on several sources, including https://www.webmedcentral.com/article_view/5000
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23862567
Curator's Comment: Description was created based on several sources, including https://www.webmedcentral.com/article_view/5000
Polydatin (PD, also named pieceid, (E)-piceid, (E)-polydatin, trans-polydatin, 3,40 ,5-trihydroxystilbene-3-b-D-glucoside) is a monocrystalline compound originally isolated from the root and rhizome of Polygonum cuspidatum Sieb. et Zucc. (Polygonaceae), a traditional Chinese medicine that has long been used in China as an analgesic, anti-pyretic, diuretic and expectorant. It is a glucoside of resveratrol (3,40 ,5-trihydroxystilbene) in which the glucoside group bound to the position C-3 substitutes a hydroxyl group, belonging to stilbene phytoalexins. Polydatin can also be detected in grape, peanut, hop cones, red wines, hop pellets, cocoa-containing products, chocolate products and many daily diets. Polydatin is the most abundant form of resveratrol in nature. Polydatin shows many pharmacological effects confirmed by numerous investigations, including cardiovascular protection, neuroprotection, anti-inflammation, immunoregulation, anti-oxidation, anti-tumour and liver and lung protective effects. Polydatin has found its way into clinical trials for the treatment of hemorrhagic shock and irritable bowel syndrome.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25449040
Curator's Comment: It has shown that PD can cross the blood–brain barrier to protect brain tissues from ischemia–reperfusion injury or cerebral ischemia
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: GO:0006629 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23862567 |
|||
Target ID: Free radical scavenging Sources: https://www.ncbi.nlm.nih.gov/pubmed/27526125 |
|||
Target ID: CHEMBL1075189 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26951145 |
128.0 µM [IC50] | ||
Target ID: CHEMBL612877 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26517558 |
95.0 µM [IC50] | ||
Target ID: Sirt1, UniProtKB - A0A0G2JZ79 Sources: https://www.ncbi.nlm.nih.gov/pubmed/26301045 |
|||
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23241098 |
Primary | Unknown Approved UseUnknown |
||
| Primary | Unknown Approved UseUnknown |
Doses
| Dose | Population | Adverse events |
|---|---|---|
40 mg 2 times / day multiple, oral Highest studied dose Dose: 40 mg, 2 times / day Route: oral Route: multiple Dose: 40 mg, 2 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: F Food Status: FED Sources: |
Other AEs: Nausea... |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Nausea | 25% | 40 mg 2 times / day multiple, oral Highest studied dose Dose: 40 mg, 2 times / day Route: oral Route: multiple Dose: 40 mg, 2 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: F Food Status: FED Sources: |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Investigation of the effects of some phenolic compounds on the activities of glucose-6-phosphate dehydrogenase and 6-phosphogluconate dehydrogenase from human erythrocytes. | 2014-11 |
|
| The stilbenes resveratrol, pterostilbene and piceid affect growth and stress resistance in mammalian cells via a mechanism requiring estrogen receptor beta and the induction of Mn-superoxide dismutase. | 2014-02 |
|
| Polydatin attenuated food allergy via store-operated calcium channels in mast cell. | 2013-07-07 |
|
| Polydatin (PD) inhibits IgE-mediated passive cutaneous anaphylaxis in mice by stabilizing mast cells through modulating Ca²⁺ mobilization. | 2012-11-01 |
|
| Plant polyphenols regulate chemokine expression and tissue repair in human keratinocytes through interaction with cytoplasmic and nuclear components of epidermal growth factor receptor system. | 2012-02-15 |
|
| Plant polyphenols differentially modulate inflammatory responses of human keratinocytes by interfering with activation of transcription factors NFκB and AhR and EGFR-ERK pathway. | 2011-09-01 |
|
| Anti-HIV activities of the compounds isolated from Polygonum cuspidatum and Polygonum multiflorum. | 2010-06 |
|
| Transport, deglycosylation, and metabolism of trans-piceid by small intestinal epithelial cells. | 2006-10 |
|
| Role of peptide primary sequence in polyphenol-protein recognition: an example with neurotensin. | 2005-11-30 |
|
| In vitro inhibition of human cGMP-specific phosphodiesterase-5 by polyphenols from red grapes. | 2005-03-23 |
|
| Cellular uptake and efflux of trans-piceid and its aglycone trans-resveratrol on the apical membrane of human intestinal Caco-2 cells. | 2005-02-09 |
|
| Potential cancer-chemopreventive activities of wine stilbenoids and flavans extracted from grape (Vitis vinifera) cell cultures. | 2001 |
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT01780129
Curator's Comment: can also be used as oral tablets; 200 mg PEA+20 mg polydatin; 2 tablets/day; 12 weeks
https://clinicaltrials.gov/ct2/show/NCT01370720
Shock treatment: dilute two 100mg/5mL vials of HW6 (Polydatin) into 500mL 0.9% NaCl injection and administer as i.v. infusion over 2 hours. The drug should be given as early as possible right after the IC Form is signed on Day 1, and once every 24 hours for additional 4 doses.
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25449040
Polydatin attenuated phenylephrine-induced inhibition of hypertrophy of murine cardiomyocytes in a concentration-dependent manner with a complete inhibition of hypertrophy at the concentration of 50 uM.
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
DSLD |
4329 (Number of products:1)
Created by
admin on Mon Mar 31 18:49:22 GMT 2025 , Edited by admin on Mon Mar 31 18:49:22 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
1364277
Created by
admin on Mon Mar 31 18:49:22 GMT 2025 , Edited by admin on Mon Mar 31 18:49:22 GMT 2025
|
PRIMARY | RxNorm | ||
|
XM261C37CQ
Created by
admin on Mon Mar 31 18:49:22 GMT 2025 , Edited by admin on Mon Mar 31 18:49:22 GMT 2025
|
PRIMARY | |||
|
XM261C37CQ
Created by
admin on Mon Mar 31 18:49:22 GMT 2025 , Edited by admin on Mon Mar 31 18:49:22 GMT 2025
|
PRIMARY | |||
|
27208-80-6
Created by
admin on Mon Mar 31 18:49:22 GMT 2025 , Edited by admin on Mon Mar 31 18:49:22 GMT 2025
|
PRIMARY | |||
|
m9549
Created by
admin on Mon Mar 31 18:49:22 GMT 2025 , Edited by admin on Mon Mar 31 18:49:22 GMT 2025
|
PRIMARY | Merck Index | ||
|
PICEID
Created by
admin on Mon Mar 31 18:49:22 GMT 2025 , Edited by admin on Mon Mar 31 18:49:22 GMT 2025
|
PRIMARY | |||
|
SUB34035
Created by
admin on Mon Mar 31 18:49:22 GMT 2025 , Edited by admin on Mon Mar 31 18:49:22 GMT 2025
|
PRIMARY | |||
|
5281718
Created by
admin on Mon Mar 31 18:49:22 GMT 2025 , Edited by admin on Mon Mar 31 18:49:22 GMT 2025
|
PRIMARY | |||
|
DB11263
Created by
admin on Mon Mar 31 18:49:22 GMT 2025 , Edited by admin on Mon Mar 31 18:49:22 GMT 2025
|
PRIMARY | |||
|
DTXSID001030555
Created by
admin on Mon Mar 31 18:49:22 GMT 2025 , Edited by admin on Mon Mar 31 18:49:22 GMT 2025
|
PRIMARY | |||
|
1546194
Created by
admin on Mon Mar 31 18:49:22 GMT 2025 , Edited by admin on Mon Mar 31 18:49:22 GMT 2025
|
PRIMARY | |||
|
C058229
Created by
admin on Mon Mar 31 18:49:22 GMT 2025 , Edited by admin on Mon Mar 31 18:49:22 GMT 2025
|
PRIMARY | |||
|
8198
Created by
admin on Mon Mar 31 18:49:22 GMT 2025 , Edited by admin on Mon Mar 31 18:49:22 GMT 2025
|
PRIMARY | |||
|
4613
Created by
admin on Mon Mar 31 18:49:22 GMT 2025 , Edited by admin on Mon Mar 31 18:49:22 GMT 2025
|
PRIMARY | |||
|
100000127888
Created by
admin on Mon Mar 31 18:49:22 GMT 2025 , Edited by admin on Mon Mar 31 18:49:22 GMT 2025
|
PRIMARY |
ACTIVE MOIETY